Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

Author： Mateo Ma Gracia   Gutierrez Ma del Mar   Vidal Francesc   Domingo Pere  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.8, 2013-06, pp. : 1055-1064

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease

By Perez Lloret Santiago   Rascol Olivier  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2221-2230

Informa Healthcare

Access to resources Recommend Favorite

Bristol-Myers Squibb has announced that it will no longer make or sell the antidepressant Serzone

By  

Reactions Weekly, Vol. 1, Iss. 1007, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Pharmacokinetic profile of once-daily cyclobenzaprine extended-release

By Darwish Mona   Hellriegel Edward T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 11, 2010-11 ,pp. : 1425-1436

Informa Healthcare

Access to resources Recommend Favorite

Treatment of HIV infection with once-daily regimens

By Permpalung Nitipong   Putcharoen Opass   Avihingsanon Anchalee   Ruxrungtham Kiat  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2301-2317

Informa Healthcare

Access to resources Recommend Favorite

Health Canada has granted a notice of compliance for Bristol-Myers Squibb's dasatinib [Sprycel] for use in patients with chronic myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1582-1583, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite